A review of the biological role of miRNAs in prostate cancer suppression and progression

Author(s):  
Ahmed S. Doghish ◽  
Ahmed Ismail ◽  
Hesham A. El-Mahdy ◽  
Mohamed A. Elkady ◽  
Mahmoud A. Elrebehy ◽  
...  
2016 ◽  
Author(s):  
Aileen M. Garcia-Vargas ◽  
Maylein C. Juan-Rivera ◽  
Milaris M. Sánchez-Cordero ◽  
Maria Sánchez-Vázquez ◽  
Krizia Rohena ◽  
...  

Author(s):  
Ying Dong ◽  
Daniela Loessner ◽  
Shirly Sieh ◽  
Anna Taubenberger ◽  
Ruth A. Fuhrman-Luck ◽  
...  

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1418 ◽  
Author(s):  
Di Zazzo ◽  
Galasso ◽  
Giovannelli ◽  
Di Donato ◽  
Bilancio ◽  
...  

Prostate cancer (PC) remains a widespread malignancy in men. Since the androgen/androgen receptor (AR) axis is associated with the pathogenesis of prostate cancer, suppression of AR-dependent signaling by androgen deprivation therapy (ADT) still represents the primary intervention for this disease. Despite the initial response, prostate cancer frequently develops resistance to ADT and progresses. As such, the disease becomes metastatic and few therapeutic options are available at this stage. Although the majority of studies are focused on the role of AR signaling, compelling evidence has shown that estrogens and their receptors control prostate cancer initiation and progression through a still debated mechanism. Epithelial versus mesenchymal transition (EMT) is involved in metastatic spread as well as drug-resistance of human cancers, and many studies on the role of this process in prostate cancer progression have been reported. We discuss here the findings on the role of estrogen/estrogen receptor (ER) axis in epithelial versus mesenchymal transition of prostate cancer cells. The pending questions concerning this issue are presented, together with the impact of the available data in clinical management of prostate cancer patients.


2021 ◽  
Vol 11 ◽  
Author(s):  
Ying Zhang ◽  
Jin-Soo Kim ◽  
Tian-Zhen Wang ◽  
Robert U. Newton ◽  
Daniel A. Galvão ◽  
...  

Physical exercise is increasingly recognized as a valuable treatment strategy in managing prostate cancer, not only enhancing supportive care but potentially influencing disease outcomes. However, there are limited studies investigating mechanisms of the tumor-suppressive effect of exercise. Recently, extracellular vesicles (EVs) have been recognized as a therapeutic target for cancer as tumor-derived EVs have the potential to promote metastatic capacity by transferring oncogenic proteins, integrins, and microRNAs to other cells and EVs are also involved in developing drug resistance. Skeletal muscle has been identified as an endocrine organ, releasing EVs into the circulation, and levels of EV-containing factors have been shown to increase in response to exercise. Moreover, preclinical studies have demonstrated the tumor-suppressive effect of protein and microRNA contents in skeletal muscle-derived EVs in various cancers, including prostate cancer. Here we review current knowledge of the tumor-derived EVs in prostate cancer progression and metastasis, the role of exercise in skeletal muscle-derived EVs circulating levels and the alteration of their contents, and the potential tumor-suppressive effect of skeletal muscle-derived EV contents in prostate cancer. In addition, we review the proposed mechanism of exercise in the uptake of skeletal muscle-derived EVs in prostate cancer.


2004 ◽  
Vol 171 (4S) ◽  
pp. 108-108
Author(s):  
Rainer Kuefer ◽  
Kathleen Day ◽  
Jonathan Rios-Doria ◽  
Matthias Hofer ◽  
Arul Chinnaiyan ◽  
...  

2020 ◽  
Author(s):  
W Kisel ◽  
S Conrad ◽  
S Füssel ◽  
U Sommer ◽  
GB Baretton ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document